Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management Advisory Committee Meeting (DSaRM)

FDA White Oak Campus, 10903 New Hampshire Avenue, Building 31 Conference Center
The Great Room (Rm. 1503), Silver Spring, Maryland
November 1, 2018

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Kalyani Bhatt, BS, MS  
Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Walter S. Dunn, MD, PhD  
Staff Psychiatrist and Assistant Clinical Professor  
West Los Angeles Veterans Administration  
Medical Center  
University of California Los Angeles  
Department of Psychiatry  
Los Angeles, California

Jess G. Fiedorowicz, MD, PhD  
Associate Professor  
Departments of Psychiatry, Epidemiology and Internal Medicine  
University of Iowa Carver College of Medicine  
Iowa City, Iowa

Satish Iyengar, PhD  
Chair and Professor of Statistics  
Department of Statistics  
University of Pittsburgh  
Pittsburgh, Pennsylvania

Felipe A. Jain, MD  
Assistant Professor of Psychiatry  
Department of Psychiatry  
Harvard Medical School  
Massachusetts General Hospital  
Boston, Massachusetts

Rajesh Narendran, MD  
(Chairperson)  
Attending Psychiatrist  
Re:solve Crisis Network  
Western Psychiatric Institute and Clinics  
Associate Professor in Radiology and Psychiatry  
Psychiatric Molecular Imaging Program  
University of Pittsburgh  
Pittsburgh, Pennsylvania

Kim O. Witczak  
(Consumer Representative)  
Co-Founder, Executive Director  
Woodymatters  
Minneapolis, Minnesota
FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management Advisory Committee Meeting (DSaRM)
November 1, 2018

MEETING ROSTER (cont.)

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Robert R. Conley, MD
(Industry Representative)
Global Development Leader
Pain and Core Therapeutic
Team and Distinguished Scholar
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana

DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEMBERS (Voting)

Kelly Besco, PharmD, FISMP, CPPS
Health-System Medication Safety Officer
OhioHealth Pharmacy Services
Dublin, Ohio

Marie R. Griffin, MD, MPH
Professor, Health Policy and Medicine
Director, Vanderbilt MPH Program
Department of Health Policy
Vanderbilt University Medical Center
Nashville, Tennessee

Laurel A. Habel, MPH, PhD
Associate Director, Cancer Research
Division of Research
Kaiser Permanente Northern California
Oakland, California

Sonia Hernandez-Diaz, MD, MPH, DrPH
Professor of Epidemiology
Department of Epidemiology
Harvard T.H. Chan School of Public Health
Boston, Massachusetts

Martin Kulldorff, PhD
Professor of Medicine and Biostatistician
Division of Pharmacoepidemiology and Pharmacoeconomics
Department of Medicine
Harvard Medical School and Brigham &Women's Hospital
Boston, Massachusetts

Steven B. Meisel, PharmD
System Director of Patient Safety
Fairview Health Services
Minneapolis, Minnesota

Anne-Michelle Ruha, MD, FACMT
Director, Medical Toxicology Fellowship Program
Department of Medical Toxicology
Banner University Medical Center
Clinical Associate Professor of Emergency Medicine
University of Arizona College of Medicine
Phoenix, Arizona

Terri L. Warholak, PhD, RPh, CPHQ, FAPhA
Professor and Assistant Dean
Academic Affairs and Assessment
College of Pharmacy
University of Arizona
Tucson, Arizona
**TEMPORARY MEMBERS (Voting)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Jane B. Acri, PhD</strong></td>
<td>Chief, Medication Discovery &amp; Toxicology Branch</td>
</tr>
<tr>
<td></td>
<td>Division of Therapeutics and Medical Consequences</td>
</tr>
<tr>
<td></td>
<td>National Institute on Drug Abuse</td>
</tr>
<tr>
<td></td>
<td>National Institutes of Health (NIH)</td>
</tr>
<tr>
<td></td>
<td>Bethesda, Maryland</td>
</tr>
<tr>
<td><strong>Stephanie Y. Crawford, PhD, MPH</strong></td>
<td>Department of Pharmacy Systems</td>
</tr>
<tr>
<td></td>
<td>Outcomes and Policy</td>
</tr>
<tr>
<td></td>
<td>University of Chicago</td>
</tr>
<tr>
<td></td>
<td>Chicago, Illinois</td>
</tr>
<tr>
<td><strong>Kathryn E. Flynn, PhD</strong></td>
<td>Associate Professor of Medicine</td>
</tr>
<tr>
<td></td>
<td>Division of Hematology and Oncology</td>
</tr>
<tr>
<td></td>
<td>Senior Scientific Director for Patient-Reported Outcomes</td>
</tr>
<tr>
<td></td>
<td>Center for International Blood &amp; Marrow Transplant Research</td>
</tr>
<tr>
<td></td>
<td>Milwaukee, Wisconsin</td>
</tr>
<tr>
<td><strong>Elizabeth Joniak-Grant, PhD</strong></td>
<td>(Patient Representative)</td>
</tr>
<tr>
<td></td>
<td>Holly Springs, North Carolina</td>
</tr>
<tr>
<td><strong>David Cella, PhD</strong></td>
<td>Professor Chairperson</td>
</tr>
<tr>
<td></td>
<td>Medical Social Sciences</td>
</tr>
<tr>
<td></td>
<td>Northwestern University Feinberg School of Medicine</td>
</tr>
<tr>
<td></td>
<td>Chicago, Illinois</td>
</tr>
<tr>
<td><strong>Harriet de Wit, PhD</strong></td>
<td>Department of Psychiatry and Behavioral Neuroscience</td>
</tr>
<tr>
<td></td>
<td>The University of Chicago</td>
</tr>
<tr>
<td></td>
<td>Chicago, Illinois</td>
</tr>
<tr>
<td><strong>Roxanne E. Jensen, PhD</strong></td>
<td>Program Director</td>
</tr>
<tr>
<td></td>
<td>Outcomes Research Branch</td>
</tr>
<tr>
<td></td>
<td>Health Care Delivery Research Program</td>
</tr>
<tr>
<td></td>
<td>Division of Cancer Control and Population Sciences</td>
</tr>
<tr>
<td></td>
<td>National Cancer Institute, NIH</td>
</tr>
<tr>
<td></td>
<td>Bethesda, Maryland</td>
</tr>
<tr>
<td><strong>Brandon D.L. Marshall, PhD</strong></td>
<td>Associate Professor</td>
</tr>
<tr>
<td></td>
<td>Department of Epidemiology</td>
</tr>
<tr>
<td></td>
<td>Brown University School of Public Health</td>
</tr>
<tr>
<td></td>
<td>Providence, Rhode Island</td>
</tr>
<tr>
<td><strong>William T. Riley, PhD</strong></td>
<td>Director</td>
</tr>
<tr>
<td></td>
<td>Office of Behavioral and Social Sciences Research</td>
</tr>
<tr>
<td></td>
<td>NIH</td>
</tr>
<tr>
<td></td>
<td>Bethesda, Maryland</td>
</tr>
</tbody>
</table>
FDA PARTICIPANTS (Non-Voting)

Robert Temple, MD  
Deputy Director for Clinical Science  
CDER, FDA  
Deputy Director (Acting)  
Office of Drug Evaluation I (ODE I)  
Office of New Drugs (OND), CDER, FDA

Mitchell Mathis, MD  
Division Director  
Division of Psychiatry Products (DPP)  
ODE I, OND, CDER, FDA

Tiffany Farchione, MD  
Deputy Director  
DPP, ODE I, OND, CDER, FDA

Daniel J. Lee, MD  
Clinical Reviewer  
DPP, ODE I, OND, CDER, FDA

Ellis Unger, MD  
Director  
ODE I, OND, CDER, FDA

Judy Staffa, PhD, RPh  
Director  
Office of Pharmacovigilance and Epidemiology  
Office of Surveillance and Epidemiology  
CDER, FDA

Dominic Chiapperino, PhD  
Director  
Controlled Substance Staff  
Office of the Center Director, CDER, FDA

Semhar Ogbagaber, PhD  
Statistician  
Division of Biometrics I  
Office of Biostatistics  
Office of Translational Sciences, CDER, FDA